News - October 20, 2020
EUCOPE, together with 33 other stakeholders active in health is delighted to invite you to the second EU Health Summit on 26 October. COVID-19 has exacerbated many of the existing, underlying problems of healthcare systems. The current crisis has clearly… read more
News - October 5, 2020
The EU and US Biotech Sector’s Response to COVID-19 On 24 September, EUCOPE, together with BIO, hosted a webinar focusing on the response of the global biotech sector to COVID-19 pandemic as well as measures taken by regulatory and policy… read more
News - September 30, 2020
Earlier this Summer the European Commission published its Roadmap for the Pharmaceutical Strategy for Europe which paved the way for a consultation process to which EUCOPE has contributed and will continue engage in the next months. Our position paper accompanying… read more
News - September 10, 2020
Given the most recent travel restrictions to and from Belgium, we would like to inform you that the EUCOPE Board has decided to have the upcoming General and Members Meetings on 14 October in a virtual format only and not… read more
News - September 7, 2020
On 24 September, EUCOPE, together with BIO, will host a webinar focused on the response of the global biotech sector to COVID-19 pandemic as well as measures taken by regulatory and policy institutions in the EU and US. The agenda… read more
Press Release - August 11, 2020
Brussels 11 August 2020 – EUCOPE, the European association for small to medium-sized companies in the field of pharmaceuticals, biotechnologies – many of which are researching and developing rare disease treatments – notes the publication of the evaluation of EU… read more
Press Release - August 11, 2020
EUCOPE, the European association for small to medium-sized companies in the field of pharmaceuticals, biotechnologies – many of which are researching and developing rare disease treatments – notes the publication of the study on the EU Regulation 141/2000 on Orphan… read more
News - July 8, 2020
In the past two decades, a combination of scientific breakthrough coupled with strong incentives systems brought about great progress for rare disease patients. The number of medicines approved in Europe to treat rare diseases since 2000 increased from 8 to… read more
News / Press Release - July 7, 2020
On the verge of the publication of the EU industrial strategy in March, EUCOPE shared the expectations and ambitions of its membership for a coherent strategy that harness Europe’s untapped potential: small and medium biopharma. The mission letter from President von… read more
News - June 25, 2020
EUCOPE invites you to an online discussion on the future of rare diseases innovation to the benefit of patients in Europe. Entitled ‘How can Europe remain at the forefront of innovation to the benefit of patients with rare diseases?’, the… read more
